Frazier Lifesciences Acquisition Corporation
Equities
NAMS
NL00150012L7
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.95 EUR | -8.14% |
|
+13.41% | +74.93% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.93% | 175.83Cr | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.65TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.62TCr | |
-20.90% | 1.54TCr | |
-46.14% | 1.52TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.35TCr |
- Stock Market
- Equities
- NAMS Stock
- News Frazier Lifesciences Acquisition Corporation
- SVB Securities Starts NewAmsterdam Pharma at Outperform With $19 Price Target